GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Feng Chi Biotech Corp (ROCO:6744) » Definitions » Debt-to-Revenue

Feng Chi Biotech (ROCO:6744) Debt-to-Revenue : 0.06 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Feng Chi Biotech Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Feng Chi Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$2.6 Mil. Feng Chi Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$8.1 Mil. Feng Chi Biotech's annualized Revenue for the quarter that ended in Dec. 2023 was NT$172.5 Mil. Feng Chi Biotech's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.06.


Feng Chi Biotech Debt-to-Revenue Historical Data

The historical data trend for Feng Chi Biotech's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Feng Chi Biotech Debt-to-Revenue Chart

Feng Chi Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial 0.05 0.03 0.01 0.07 0.06

Feng Chi Biotech Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.01 0.08 0.07 0.06

Competitive Comparison of Feng Chi Biotech's Debt-to-Revenue

For the Biotechnology subindustry, Feng Chi Biotech's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Feng Chi Biotech's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Feng Chi Biotech's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Feng Chi Biotech's Debt-to-Revenue falls into.



Feng Chi Biotech Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Feng Chi Biotech's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.649 + 8.149) / 180.578
=0.06

Feng Chi Biotech's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.649 + 8.149) / 172.45
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.


Feng Chi Biotech Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Feng Chi Biotech's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Feng Chi Biotech (ROCO:6744) Business Description

Traded in Other Exchanges
N/A
Address
No. 5, Shaoxing North Street, 5th Floor-1, Zhongzheng District, Taipei City, TWN, 100
Feng Chi Biotech Corp provide promotion and support for clinical testing and molecular genetic medicine research related technologies. The company's products and services include clinical testing, food testing, newborn screening, prenatal screening, iron stomach, interscience, and colony counting.

Feng Chi Biotech (ROCO:6744) Headlines

No Headlines